Severity of symptoms at enrolment into WATCH trial (baseline) compared with primary endpoint time (day 7), stratified by AOM resolution at Day 7.</p
Comparison of observed start and end week of norovirus warning phase and predicted start and end wee...
<p>Baseline cytokines measurements in pg/ml of patients with available primary endpoint.</p
<p>Tests are named at the top of each column. VOSP is the Visual Object and Space Perception battery...
The distribution of scores within each time point is plotted using a combination of a violin (repres...
<p>A) Mean duration computed by VP scores (high or low) relative to the median score as a function o...
Primary and secondary endpoint measures compared by timing to start rivaroxaban administration.</p
Baseline parameters and angiography details for elective and acute trial participants.</p
(A) The total number of symptoms reported on the SCAT3 increased from preseason to 6-days following ...
Clinical outcomes at endpoint with baseline comparisons on: electrocardiogram readout, and reported ...
<p>The filled circles connected with dashed line represent the evaluator A, while the filled squares...
Mean Global Severity Indices on the revised version of the symptom checklist with 90 items between b...
Patient and doctor characteristics at baseline, 6-month follow-up (trial endline), and 18-month foll...
Mean values of the principal outcome measures: BCVA and CST in 56 eyes with UME at baseline and thro...
Delay between baseline screening and time of onset of disease for 17 VL casesin relation to their in...
<p>Comparison of AFP levels at baseline and at 4–8 weeks following first-line treatment, based on tr...
Comparison of observed start and end week of norovirus warning phase and predicted start and end wee...
<p>Baseline cytokines measurements in pg/ml of patients with available primary endpoint.</p
<p>Tests are named at the top of each column. VOSP is the Visual Object and Space Perception battery...
The distribution of scores within each time point is plotted using a combination of a violin (repres...
<p>A) Mean duration computed by VP scores (high or low) relative to the median score as a function o...
Primary and secondary endpoint measures compared by timing to start rivaroxaban administration.</p
Baseline parameters and angiography details for elective and acute trial participants.</p
(A) The total number of symptoms reported on the SCAT3 increased from preseason to 6-days following ...
Clinical outcomes at endpoint with baseline comparisons on: electrocardiogram readout, and reported ...
<p>The filled circles connected with dashed line represent the evaluator A, while the filled squares...
Mean Global Severity Indices on the revised version of the symptom checklist with 90 items between b...
Patient and doctor characteristics at baseline, 6-month follow-up (trial endline), and 18-month foll...
Mean values of the principal outcome measures: BCVA and CST in 56 eyes with UME at baseline and thro...
Delay between baseline screening and time of onset of disease for 17 VL casesin relation to their in...
<p>Comparison of AFP levels at baseline and at 4–8 weeks following first-line treatment, based on tr...
Comparison of observed start and end week of norovirus warning phase and predicted start and end wee...
<p>Baseline cytokines measurements in pg/ml of patients with available primary endpoint.</p
<p>Tests are named at the top of each column. VOSP is the Visual Object and Space Perception battery...